Literature DB >> 10556977

Tissue transglutaminase is a caspase substrate during apoptosis. Cleavage causes loss of transamidating function and is a biochemical marker of caspase 3 activation.

M Fabbi1, D Marimpietri, S Martini, C Brancolini, A Amoresano, A Scaloni, A Bargellesi, E Cosulich.   

Abstract

Tissue transglutaminase (tTG) is a Ca2+-dependent cross-linking enzyme that participates in the apoptotic machinery by irreversibly assembling a protein scaffold that prevents the leakage of intracellular components. In the present study a single-chain antibody fragment (scFv) detecting tTG is described. We demonstrate that TG/F8 scFv, selected from a phase display library of human V-gene segments by binding to guinea-pig liver tTG, can react with human tTG both in Western blot and in immunohistochemistry. The specific detection of tTG by TG/F8 in human thymocytes is verified by mass spectrometric analysis of the purified protein. Furthermore, we demonstrate that in lymphoid cells tTG is cleaved by caspase 3 during the late phase of apoptotic death, concomitant to DNA fragmentation, and that such cleavage causes loss of cross-linking function. We propose tTG cleavage as a valuable biochemical marker of caspase 3 activation during the late execution phase of apoptosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10556977     DOI: 10.1038/sj.cdd.4400573

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  12 in total

1.  Interleukin-1 induces pro-mineralizing activity of cartilage tissue transglutaminase and factor XIIIa.

Authors:  K Johnson; S Hashimoto; M Lotz; K Pritzker; R Terkeltaub
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

2.  Down-regulation of the serotonin transporter in hyperreactive platelets counteracts the pro-thrombotic effect of serotonin.

Authors:  Endrit Ziu; Charles P Mercado; Yicong Li; Preeti Singh; Billow A Ahmed; Samuel Freyaldenhoven; Shelly Lensing; Jerry Ware; Fusun Kilic
Journal:  J Mol Cell Cardiol       Date:  2012-02-15       Impact factor: 5.000

3.  Down-regulation of tTG expression by RNAi inhibits HSC proliferation and attenuates liver fibrosis.

Authors:  Gang Zhao; Zhi-Qi Zhang; Bin Zhang; Meng Luo; Yong-Wei Sun; Zhi-Yong Wu
Journal:  Int J Clin Exp Pathol       Date:  2011-06-12

4.  Tissue transglutaminase, protein cross-linking and Alzheimer's disease: review and views.

Authors:  Deng-Shun Wang; Dennis W Dickson; James S Malter
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

Review 5.  Transglutaminases: nature's biological glues.

Authors:  Martin Griffin; Rita Casadio; Carlo M Bergamini
Journal:  Biochem J       Date:  2002-12-01       Impact factor: 3.857

6.  Dual induction of caspase 3- and transglutaminase-dependent apoptosis by acyclic retinoid in hepatocellular carcinoma cells.

Authors:  Hideki Tatsukawa; Tetsuro Sano; Yayoi Fukaya; Naoto Ishibashi; Makiko Watanabe; Masataka Okuno; Hisataka Moriwaki; Soichi Kojima
Journal:  Mol Cancer       Date:  2011-01-09       Impact factor: 27.401

7.  Clot Formation in the Sipunculid Worm Themiste petricola: A Haemostatic and Immune Cellular Response.

Authors:  Tomás Lombardo; Guillermo A Blanco
Journal:  Int J Cell Biol       Date:  2012-03-25

Review 8.  Death, autoantigen modifications, and tolerance.

Authors:  P J Utz; T J Gensler; P Anderson
Journal:  Arthritis Res       Date:  2000-02-09

9.  Prostate transglutaminase (TGase-4, TGaseP) enhances the adhesion of prostate cancer cells to extracellular matrix, the potential role of TGase-core domain.

Authors:  Wen G Jiang; Lin Ye; Andrew J Sanders; Fiona Ruge; Howard G Kynaston; Richard J Ablin; Malcolm D Mason
Journal:  J Transl Med       Date:  2013-10-25       Impact factor: 5.531

10.  Inhibitory effects of fenretinide metabolites N-[4-methoxyphenyl]retinamide (MPR) and 4-oxo-N-(4-hydroxyphenyl)retinamide (3-keto-HPR) on fenretinide molecular targets β-carotene oxygenase 1, stearoyl-CoA desaturase 1 and dihydroceramide Δ4-desaturase 1.

Authors:  Eugenia Poliakov; William Samuel; Todd Duncan; Danielle B Gutierrez; Nathan L Mata; T Michael Redmond
Journal:  PLoS One       Date:  2017-04-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.